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Abstract 
 
Bacteria use secretion systems to export proteins from inside of the bacterium into the 
periplasm, extracellular space, or host cell. Within the Mycobacterium genus, the type VII 
secretion systems (T7SS) transport products across the unusually thick and waxy 
mycobacterial envelope. T7SS are of particular importance because they are involved in the 
virulence of pathogenic mycobacteria. Mycobacteria have as many as five distinct T7SS 
called ESX systems. ESX-1, 3, and 5, have demonstrated roles in viability and virulence in 
certain pathogenic species like M. tuberculosis and M. marinum. Our research focuses on the 
ESX-4 apparatus, the ancestral system that gave rise to the other ESX systems. Although 
ESX-4 is the smallest, it shares the hallmark characteristics of ESX systems including a 
membrane protein complex and predicted secreted substrates containing a WXG100 motif 
necessary for secretion. In M. smegmatis, ESX-4 is required for Distributive Conjugal 
Transfer (DCT), a form of horizontal gene transfer during which a donor cell transfers 
segments of its genome to a recipient cell, which can lead to the transfer of traits such as 
antibiotic resistance. However, the mechanism of protein secretion via the ESX-4 system is 
still unknown. Through a mycobacterial protein fragment two-hybrid complementation 
assay, we will identify protein interactions within the ESX-4 system. As bacterial mRNA is 
polycistronic, we will initially examine interactions of proteins encoded on the same mRNA. 
These high priority proteins include putative ESX secreted products. Our results will 
demonstrate protein-protein interactions relevant to the ESX-4 system of M. smegmatis, 
which will allow us to further understand its mechanism of secretion and increase our 
knowledge of T7SS. 
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Introduction 
 
I. Mycobacterium tuberculosis in a historic context 
a. Current state of Tuberculosis infection  
In 2017, there were approximately 10 million new cases of active tuberculosis 
infection reported in all countries and age groups. With 1.6 million deaths that year, 
tuberculosis is recognized as the leading cause of death from an infectious agent in the world. 
Although 83% of cases are successfully treated, tuberculosis is especially concerning due to 
the high prevalence of antibiotic resistant strains and health care providers are quickly 
running out of viable treatment options. Tuberculosis is caused by infection with a bacterium 
called Mycobacterium tuberculosis (Mtb). Understanding the mechanisms and specific 
characteristics of M. tuberculosis would enable researchers to create more efficient treatment 
options for the millions of affected individuals (“WHO | 10 facts on tuberculosis,” n.d.).  
 
b. History of TB infection and discovery of Mtb  
It is thought that the genus Mycobacterium originated more than 150 million years 
ago and evidence of infection in humans dates back 3,300 and 2,300 years as written in 
documents found in India and China, respectively. Tuberculosis infection can be traced 
throughout history, with mentions of the disease as phthisis or consumption in ancient Greek 
and Roman documents. After the fall of the Roman Empire, the disease was common in 
Europe and was pervasive throughout the Middle Ages. The exact pathological and 
anatomical description was created in 1679 by Francis Sylvius in his work Opera Medica, 
where he describes the progression of the disease symptoms. Soon after, an Italian health law 
was passed that banned consumptives from being treated in public hospitals and established 
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designated locations for their treatment, which was the first official reference to the 
infectious nature of the disease. 
 During the 18th century tuberculosis had become an epidemic in Europe, in part due 
to the Industrial Revolution and poor social conditions including malnutrition, poorly 
ventilated and crowded housing, and primitive sanitation systems. At the beginning of the 
19th century, the scientific community was engaged in a debate regarding the origins of the 
disease. Some believed that it was infectious, others that it was hereditary, and others that it 
was some form of cancer. Throughout the 19th century, various discoveries were made that 
pointed towards the infectious nature of the disease which was eventually demonstrated in 
1865 by Jean-Antoine Villemin when he injected a rabbit with liquid from a tuberculous 
cavity from an individual who had died. The rabbit remained alive and did not display any 
symptoms but after an autopsy, extensive demonstrated signs of infection were discovered. 
Eventually, scientist Robert Koch was able to isolate the tubercule bacillus after using 
methylene blue staining and cultivating the bacillus in animal serum. This was a landmark 
discovery and represented a turning point for the scientific community in the search for a 
greater understanding of the disease and cure (Barberis et al., 2017) 
 
II. M. tuberculosis infection 
a. Mode of TB transmission 
It has now been established that tuberculosis infection is transmitted through 
aerosolized droplet infection. When an individual with active tuberculosis infection coughs 
or sneezes, droplets are expelled that contain the Mtb bacteria. Infection is transmitted when 
an uninfected individual inhales those droplets, thus introducing the bacteria into their 
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system. Although diseases like the cold and flu are spread in the same way, TB is not as 
contagious and requires prolonged exposure with an infected individual to cause infection. 
Additionally, most individuals with healthy immune systems are able to destroy Mtb bacteria 
if exposed and do not become infected. Furthermore, not all individuals infected with TB 
display symptoms and are contagious. This is known as latent TB infection and most 
individuals with latent TB will never develop the active infection (“Tuberculosis (TB) - 
Causes - NHS.”) 
 
b. Populations most affected by TB 
Certain populations are at greater risk for infection by TB. Those with compromised 
immune systems, particularly due to chemotherapy and HIV infection are at a much higher 
risk of infection and death from TB. According to the World Health Organization, TB is the 
leading cause of death of people infected with HIV and a person living with HIV is 20 to 30 
times more likely to develop an active TB infection (“WHO | 10 facts on tuberculosis,” n.d.). 
Additionally, individuals that are very young or very old are at greater risk for active 
infection due to their immune systems generally being weaker than healthy adults. People 
that live in crowded conditions or that are in poor health because of lifestyle problems such 
as drug and alcohol misuse also tend to have weaker immune systems and are thus at higher 
risk of infection (“Tuberculosis (TB)—Causes—NHS,” n.d.). In the United States, people 
who had experienced homelessness within a year of infection accounted for 4.3% of new 
cases in 2017 (Stewart et al., 2018). Another high-risk factor is proximity to individuals 
infected with the disease. Since it is contagious, people who live in or have visited countries 
or areas with high levels of TB are at high risk. As of 2017, eight countries account for two 
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thirds of new cases. India had the greatest number of new cases, followed by China, 
Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Within the 
United States, the rate of tuberculosis infection was fifteen times higher among non-U.S.-
born persons compared to U.S.-born persons. The highest TB rate among all racial/ethnic 
groups of non-U.S.-born individuals was among Asians with 27.0 cases per 100,000 
individuals reported followed by Blacks with 25.0 cases per 100,000 individuals. 
 For U.S.-born persons, the highest TB rates were reported among Native Hawaiians 
and Pacific Islanders with 6.5 cases per 100,000 individuals followed by American Indians 
and Alaska Natives with 3.7 cases per 100,000 individuals (Stewart et al., 2018). 
Additionally, TB infection is of great concern within migrant populations and those affected 
by humanitarian crises. Crises often cause harm to human health either directly through 
violence or indirectly through lack of basic necessities like shelter, food, clean water, and 
clothing. During humanitarian crises, infectious disease is often the most significant cause of 
ill health and in the case of TB, although the incidence will vary based on country 
background and epidemiology, the rate of infection will be higher compared to pre-crisis 
levels (Zenner, 2017).  
 
III. M. tuberculosis challenges faced and current state of research 
a. Classification of drug resistant TB 
The rapid emergence of multidrug resistant TB (MDR-TB), extensively drug resistant 
TB (XDR-TB), and totally drug resistant TB (TDR-TB) is of great concern. In 2017, there 
were approximately 490,000 cases of MDR-TB and less than a 50% survival rate in patients 
that receive the recommended WHO treatment (Tiberi et al., 2018). MDR-TB is caused by 
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strains of TB that are resistant to rifampicin and isoniazid, two of the first line anti-TB drugs. 
XDR-TB is classified by strains that are resistant to rifampicin, isoniazid, along with 
fluoroquinolone and at least one of the injectable second-line drugs. Recently, certain strains 
of TB have been discovered that are resistant to all antibiotics available for testing, which is 
known as TDR-TB. A better understanding of the mechanisms by which mycobacteria 
acquire drug resistance and the action of anti-TB drugs is imperative for the development of 
new therapeutics and preventing the increasing development of drug resistance (Palomino & 
Martin, 2014).  
 
b. Treatment of TB infection 
Treatment of drug susceptible TB runs a course of approximately six months, 
beginning with a combination of rifampicin, isoniazid, pyrazinamide, and ethambutol for the 
first two months and then rifampicin and isoniazid for an additional four months. Treatment 
of MDR-TB consists of an intensive treatment course of at least eight months and includes 
four or more second-line drugs with the entire treatment course lasting 20 months. In 
addition to being difficult to treat, MDR-TB strains are ten times more transmissible than 
drug susceptible strains. XDR-TB intensive treatment is longer than eight months and 
includes the use of third-line anti-TB drugs and the total treatment course lasts longer than 
MDR-TB. Many studies have linked the increase in drug resistant TB to misdiagnosis and 
mismanagement of drug susceptible TB so improving detection of the disease, the creation of 
proper treatment plans, and patient adherence to treatment plans are needed to prevent 
increasing levels of drug resistant TB (Poce & Biava, 2015). Low patient adherence to 
treatment plans is often due to lengthy treatment durations, complex multidrug regimens, 
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adverse side effects, and unreliable public health systems and drug availability. Therefore, 
the development of more effective and efficient treatment methods is crucial to improving 
patient adherence and halting the development of drug resistant TB (Torfs et al., 2019). 
 
c. Mechanisms of drug resistance by Mtb 
There are several mechanisms by which M. tuberculosis can develop drug resistance. 
The first includes mutations in a gene that would lead to an alteration of the drug target 
binding site. For example, resistance to rifampicin is due to a mutation in the gene rpoB that 
encodes the β-subunit of RNA polymerase which is the drug target binding site. Rifampin 
blocks the exit tunnel for RNA elongation and inhibits the process of transcription so a 
mutation to the β-subunit of RNA polymerase could prevent rifampin from successfully 
binding and shutting down transcription (Qi et al., 2016). Another mechanism of resistance 
includes mutation leading to the loss of the ability to activate a prodrug, or a biologically 
inactive compound which can be metabolized in the body to produce a drug. Both isoniazid 
and pyrazinamide are prodrugs that require bioactivation and resistance to these drugs are 
caused by mutations in the structures responsible for their activation. Without activation, 
both drugs are ineffective and will not treat TB. 
 Certain drug resistant TB strains are able to enzymatically inactivate certain drugs 
like penicillin. Mtb has a class of β-lactamases that, when normally expressed, leads to 
resistance to penicillin. Lastly, certain strains of Mtb are drug resistant due to the action of 
efflux pumps, which are transport proteins involved with the extrusion of toxic substrates, 
which include virtually all classes of antibiotics, from within cells to the external 
environment (Poce & Biava, 2015). Several strategies are being explored for overcoming 
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drug resistance in TB including developing faster diagnostic methods, developing new drugs 
that act upon well-known targets, new drugs that act upon new targets, new drug 
combinations, and developing inhibitors of drug-modifying enzymes or efflux pumps 
(Webber & Piddock, 2003).  
 
d. Developments in TB treatment through the years 
The state of TB treatment has been constantly changing and developing for the past 
century. In terms of vaccines and prevention, the Bacille Calmette-Guérin (BCG) vaccine is 
currently the only available TB vaccine. First used in humans in 1921, the BCG vaccine is a 
live attenuated bacterial vaccine derived from M. bovis that was initially isolated in 1902 and 
cultured for 13 years until it lost its virulence. There are now approximately 10 
manufacturing strains of the vaccine in use and the WHO currently recommends BCG 
vaccination of all healthy newborns at birth in countries or settings with a high incidence of 
TB infection  (“WHO | BCG vaccine,” n.d.). If it cannot be administered at birth, it should be 
given at the earliest possible opportunity and is safe to be inoculated with multiple vaccines 
at once (“Fact Sheets | Infection Control & Prevention | Fact Sheet—BCG Vaccine | TB | 
CDC,” 2018). 
 Recently there has been trials of new vaccines against active TB infection. In a recent 
clinical trial, vaccine candidate M72/AS01E was able to elicit an immune response and 
prevent HIV-negative patients diagnosed with latent TB from progressing to active 
pulmonary TB for at least three years. Although this vaccine still requires much additional 
testing and conformation, these results are promising for the future (Tait et al., 2019). Other 
possible treatments focus on targeting novel mycobacterial drug targets like macromolecules 
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involved with the structure of the cell wall and protein synthesis, disrupting pathways that 
allow for the formation of drug-tolerant bacteria, and the development of host-directed 
therapy which would modulate immune responses to target specific pathways and/or reduce 
symptoms during infection (Torfs et al., 2019). Other recent developments have included the 
creation of new and faster diagnostic methods that are able to detect the presence of Mtb 
bacteria as well as any single nucleotide polymorphisms (SNPs) and mutations that are 
associated with drug resistance (Poce & Biava, 2015).  
 
IV. Overview of Mycobacterium genus and M. smegmatis as a research organism 
a. Characteristics of Mycobacterium genus 
As of December 2016, there are approximately 170 recognized species of 
Mycobacteria that vary widely in their ability to cause disease in humans. Some species are 
classified as being strict pathogens, some being non-pathogenic, and some being 
opportunistic pathogens (Forbes, 2017). Mycobacteria is a genus of bacteria characterized by 
their rod shape and the presence of mycolic acids within their cellular envelope (Houben et 
al., 2014). Mycolic acids are 2-alkyl, 3-hydroxy long chain fatty acids that, along with 
arabinogalactan and peptidoglycan form the bacterial outer membrane, also known as the 
mycomembrane (Figure 1). 
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Figure 1. Typical mycolic acid structure. Characterized by a shorter a-hydroxy hydrocarbon 
chain and a longer b-hydroxy meromycolic hydrocarbon chain. Mycolic acids can vary based 
on hydrocarbon length (denoted by a, b, c, d) or by the presence of functional groups at the Y 
and X positions (Druszczyńska et al., 2017).  
 
 
Mycolic acids occur within all examined mycobacterial species to date. Within 
mycobacteria, they typically contain 60-90 carbon atoms but a large diversity of chain 
lengths and chemical properties exist within the various species (Figure 1) (Marrakchi et al., 
2014). The mycomembrane is a second, hydrophobic membrane that surrounds the 
cytoplasmic membrane of mycobacteria. The cell wall elements are involved with several 
cellular processes including signaling, virulence, antibiotic resistance, and immune 
responses. The thick mycolic acid layer protects the mycobacteria from outside disturbances 
like mechanic and chemical stress, desiccation, antimicrobial treatments, and thus allows 
them to persist and resist various types of medical treatment (Figure 2) (Houben et al., 2014). 
Specifically, the low permeability of the cellular wall to hydrophilic drugs contributes to drug 
resistance characteristic of mycobacteria. And as permeability is directly connected to 
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fluidity, the longer the chain of the mycolic acids, the less fluid the cell wall, and the less 
permeable the cell wall (Druszczynska et al., 2017). 
 
Figure 2. Diagram of the mycobacterial cell wall. The cell wall consists of thin layers of 
peptidoglycan and arabinogalactan along with the thick layer of mycolic acids (Brown et al., 
2015). 
 
 
b. Overview of Mycobacterium pathogenicity 
 Within the Mycobacterium genus there are pathogenic, non-pathogenic, and 
opportunistic pathogen species. A large amount of effort has been dedicated to specifically 
identifying and categorizing all the species of mycobacteria due to the increasing number of 
infections caused by nontuberculous mycobacteria. In order to properly manage these 
infections in a clinical setting, it is imperative to know which specific species of 
mycobacteria is causing the infection. Although mycobacteria share various characteristics, 
many species are unique, especially in the ways that they interact with a host (Forbes, 2017). 
For example, Mycobacterium abscessus is a species of pathogenic nontuberculous 
mycobacteria (NTM) that causes skin and soft tissue infections, central nervous system 
infections, and serious lung infections in persons with chronic lung diseases like cystic 
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fibrosis. M. abscessus is especially difficult to treat due to certain strains developing 
antimicrobial drug resistance making it resistant to disinfectants and leading it to cause post-
surgical infections (Lee et al., 2015). Treatment of M. abscessus typically requires testing 
various antibiotics to see which will effectively treat the infection (“Mycobacterium 
abscessus in Healthcare Settings | HAI | CDC,” 2019). 
 Another species of pathogenic NTM that causes infection in humans is M. bovis. 
Most commonly found in cattle and other ungulates like bison, elk, and deer, M. bovis can 
cause TB infection in humans (“Fact Sheets | General | Mycobacterium bovis (Bovine 
Tuberculosis) in Humans | TB | CDC,” 2018). Although infection with M. bovis is now 
uncommon due to the pasteurization of milk and improved disease control within cattle, M. 
bovis is still considered a cause of concern in countries outside of the U.S. (Lan et al., 2016). 
Understanding the mechanisms and features of these pathogenic mycobacteria is necessary 
for designing effective treatment plans especially considering the increasing prevalence of 
multidrug resistant mycobacteria. 
 
c. Mycobacterial model organisms and M. smegmatis 
 Most of the pathogenic species including M. tuberculosis, and M. leprae, (the 
bacterium responsible for leprosy), are slow growing and working with them requires a high-
level laboratory safety protocol. M. tuberculosis is a Category 3 human pathogen and 
working with Mtb requires a biosafety level three facilities and carries with it the possibility 
of exposure. Therefore, substituting other species of mycobacteria as model organisms is 
needed. These models are particularly useful in characterizing systems and biochemical 
pathways that are conserved throughout mycobacteria. The use of genus-inclusive model 
 
   
 
   
 
Boerboom 15 
organisms is validated by recognizing that current antimicrobials have conserved targets in 
model organisms. Mycobacterial model organisms can also provide insights into molecular 
machines, such as secretion systems that function during virulence (Shiloh & Champion, 
2010). 
 Conveniently, M. smegmatis, a non-pathogenic species of mycobacteria, is used as a 
model organism for studying pathogenic mycobacteria because it is fast growing and shares 
many genes and characteristics with the pathogenic species (Gray et al., 2016). It is also 
easily genetically manipulated and has contributed to the development of plasmids for 
mycobacterial transformation and the isolation of M. smegmatis strains that are permissible 
to transformation. Ultimately, discoveries made in mycobacterial model organisms are able 
to inform future studies in pathogenic mycobacteria and are able to provide a direct 
comparison to those studies to demonstrate shared and divergent pathways (Shiloh & 
Champion, 2010).   
 
V. Bacterial secretion systems 
a. Overview of bacterial secretion systems 
There is much interest in mycobacterial research focused on the mechanisms 
associated with protein secretion. Although the layer of mycolic acids surrounding the 
cytoplasm acts as a protective barrier from external threats, that barrier makes the secretion 
of proteins more difficult. Protein secretion is an essential process for prokaryotic organisms 
by which proteins are transported from the cytoplasm of the bacteria out into the 
environment, other parts of the cell, or into another host cell (Green & Mecsas, 2016). 
Additionally, secreted proteins are often directly associated with virulence mechanisms in 
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pathogenic bacteria (Lee, 2001). These proteins can be responsible for promoting attachment 
to eukaryotic cells, acquiring resources in an environmental niche, or directly disrupting host 
cell function.  
There are various types of secretion systems and their mechanisms can depend on a 
variety of factors including how many membranes the proteins need to cross and the type of 
protein being secreted. Although the discussion of all types of bacterial secretion systems is 
outside the scope of this report, understanding the system by which pathogenic bacteria 
secrete proteins will allow for the possible development of additional treatments, as the 
disruption of secretion systems would likely prevent the bacteria from causing further 
infection (Green & Mecsas, 2016).  
 
b. Mycobacterial secretion systems 
 Mycobacteria utilize specialized mechanisms in order to transport proteins across 
their inner membrane and outer mycomembrane. Originally identified within M. tuberculosis 
in 2003, these mechanisms are known as Type VII secretion systems (T7SS). The structural 
components of T7SS and the secreted substrates are frequently encoded in linked gene 
clusters. In total, five different T7SS have been identified in mycobacteria named ESX 
systems one through five (ESX-1 through ESX-5).  Although each ESX system is unique, 
certain characteristics unify the ESX systems across the different species of mycobacteria. 
First, ESX systems contain genes that encode for small secreted proteins (~100 amino acids) 
that contain a WXG motif (Vaziri & Brosch, 2019). This means that the proteins have a 
conserved Trp-X-Gly amino acid sequence pattern that allows the secreted protein to form a 
helix-turn-helix structure (Figure 4). Second, ESX systems are identifiable by genes that 
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encode for transmembrane proteins which aid in the secretion of substrates. There are certain 
transmembrane proteins that are conserved across the different ESX systems and are thus 
named Ecc proteins or ESX conserved components (Figure 3) (Famelis et al., 2019). While 
the inner-membrane machinery has been explored more extensively, little is known about 
how ESX exported proteins are transported from the mycobacterial outer membrane into the 
extracellular environment (Vaziri & Brosch, 2019). 
 
 
Figure 3. Model for T7SS. Esx proteins are secreted as dimers by the T7SS machinery. The 
ESX conserved components are denoted EccA through EccE. The channel in the outer 
membrane is still yet to be identified (Houben et al., 2014).  
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VI. Protein secretion via ESX secretion systems 
a. Characteristics of ESX secreted proteins 
 Even though there are five total ESX systems, only ESX-3 and ESX-4 are found in 
all species of mycobacteria. The ESX-2 and ESX-5 systems are only present in slow-growing 
bacteria. Extensive research on the ESX-1 system of M. tuberculosis showed that many of its 
substrates require a protein “partner” in order to be co-secreted (Champion et al., 2014). The 
co-secreted proteins typically contain the WXG motif which allows them to dimerize with 
their partners and form the double helix structure typical of substrates secreted by ESX 
systems. The two-helix hairpin secreted proteins are dependent on each other for stability and 
form a tight dimer held together by extensive hydrophobic interactions (Figure 4). It is 
important to note that these WXG proteins are expressed and secreted by multiple types of 
ESX systems in both pathogenic and non-pathogenic bacteria and their functions are still 
being defined (Callahan et al., 2010).  
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Figure 4. Structures of T7SS substrates EsxA and EsxB. WXG motifs are shown in red and 
the secretion signal motif YxxxD/E is shown in orange. (Houben et al., 2014) 
 
 
b. ESX system functions and variation among species 
The same ESX system can also serve a different purpose in different species. For 
instance, ESX-1, ESX-3, and ESX-5 have been found to contribute to the virulence of M. 
tuberculosis with ESX-1 being responsible for the secretion of the main virulence factors of 
M. tuberculosis (Tiwari et al., 2019) and ESX-5 is responsible for the transport of proteins, 
cell wall integrity, and full virulence (Bottai et al., 2012). The attenuated strain of M. bovis 
utilized in the BCG vaccine does not contain ESX-1, further demonstrating its involvement 
in the secretion of virulence factors of mycobacteria (Champion et al., 2014). It would then 
be easy to assume then that ESX-1 is responsible for the secretion of virulence factors in all 
mycobacteria but M. abscessus, a pathogenic mycobacterium, does not have ESX-1 and its 
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virulence factors instead seem to be secreted by ESX-4 (Laencina et al., 2018). The diversity 
of functions of the ESX systems within mycobacteria is fascinating and further research is 
needed to understand their complexities. 
 Other than secreting virulence factors, the ESX systems are involved in a variety of 
processes such as the regulation of metals, and intracellular communication. ESX-3 has been 
confirmed to be involved in iron and zinc metabolism in both metal limited and metal 
sufficient conditions in M. tuberculosis (Serafini et al., 2013). One ESX system, ESX- 4, is 
particularly interesting due to its importance with a specific form of horizonal gene transfer 
(HGT), known as Distributive Conjugal Transfer (DCT) in M. smegmatis (Figure 5). Bacteria 
utilize HGT to move genetic material from one organism to another, allowing for genetic 
diversification and mitigating the constraints of asexual reproduction (Gray et al., 2013). 
Conjugation, a form of HGT, is described as the process by which DNA, usually in the form 
of plasmids and integrative conjugal elements, is passed from a donor to recipient bacteria. In 
mycobacteria, conjugation transfers chromosomal sequences, not plasmids and thus is a 
process by which a donor strain transfers a portion of its genome to a genetically distinct 
recipient strain. This process is known as Distributive Conjugal Transfer (DCT) and it 
produces mosaic progeny that displays genetic diversity similar to genetic mixing observed 
through meiotic recombination of sexual organisms (Figure 6). 
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Figure 5. ESX-4 secretion mechanism in M. smegmatis. Ecc proteins are labeled and 
proteins EsxU and EsxT are demonstrated as being secreted through the mechanism. The star 
denotes secreted protein pairs yet to be confirmed.  
 
 
 Through DCT, certain traits like antibiotic resistance or mutations can be passed 
along so understanding how DCT contributes to increasing genetic diversity is essential to 
predicting bacterial evolution rates and gene flow through strains. The Derbyshire/Gray Lab 
has discovered that a functional ESX-1 system in both donor and recipient, and a functional 
ESX-4 system in the recipient, are required for DCT (Gray et al., 2016). Although ESX-4 is 
the most ancestral ESX system, much is still unknown about its functions and mechanism of 
protein secretion within M. smegmatis.  
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Figure 6. Example of the mosaic genome that results from DCT which is represented 
by circos plots of recipient chromosomes after DCT. The yellow segments represent the 
DNA of the recipient and the blue segments represent segments of DNA received from the 
donor. The green segments correspond to a gene that corresponds to antibiotic Kanamycin 
resistance (Gray & Derbyshire, 2018).  
 
 
c. Methods of studying protein interactions in Mycobacteria 
 With such a diversity of important functions, understanding the mechanism and 
function of ESX-4 is vital to understanding Type VII secretion systems as a whole. And part 
of understanding its mechanism is knowing how and what proteins secreted by ESX-4 
interact and are secreted together. Exploring protein functions is important to understanding 
how they function in complexes, play a role in complex pathways, form enzymatic 
complexes, and how they are secreted from the cell. Various methods are available to study 
protein interactions including co-immunoprecipitation, crystallography, and tandem affinity 
purification among others, but these methods require large amounts of data and complex 
techniques. The yeast two-hybrid (Y2H) system is a more cost effective and technically 
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accessible method that can detect direct interactions between two specific proteins. This is 
done by using genetically modified yeast strains that contain a modified reporter gene, which 
when transcribed leads to a specific phenotype, usually survival on restrictive growth 
medium. The two proteins of interest are fused with either the DNA binding domain (DBD), 
referred to as the “bait”, and the activation domain (AD), referred to as the “prey”. If the two 
proteins interact, the DBD and AD will interact allowing for the transcription of the reporter 
gene and the visualization of the specific phenotype (“Yeast two-hybrid (Y2H) principle,” 
n.d.). 
 Within mycobacteria, a similar technique to Y2H can be used in M. smegmatis called 
mycobacterial protein fragment complementation (M-PFC). This technique is useful as it 
allows for protein interactions in a native environment and proteins from pathogenic bacteria 
can be utilized without concern of accidental lab exposure and virulence. The assay works 
through the use of the enzyme DHFR and the antibiotic trimethoprim. A complete and 
functional mammalian Dihydrofolate Reductase Recombinant Protein (mDHFR) enzyme 
allows for the growth of mycobacteria on plates containing the antibiotic trimethoprim. The 
gene fragments of the two proteins of interest are added to plasmids that each contain a 
fragment of mDHFR. As the plasmid is transcribed, the protein is made with the fragment of 
DHFR attached. If the two proteins of interest interact, the two fragments of mDHFR will be 
brought together, made functional, and allow the mycobacteria to grow on trimethoprim 
plates (Figure 7). 
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Figure 7. Diagram illustrating the principle of the M-PFC. Interacting proteins will bring 
together the fragments of mDHFR [FI,2] and [F3], which will result in growth on media 
containing trimethoprim. Proteins that do not interact will not bring together the fragments of 
mDHFR and no growth will occur (Singh et al., 2006). 
 
 
VII. The research problem 
 The focus of this senior thesis project is on the identification of proteins secreted via 
the ESX-4 system within M. smegmatis. In order to determine if certain proteins of interest 
interact and are co-secreted by ESX-4, we designed and conducted a mycobacterial protein 
fragment two-hybrid complementation assay. A total of seven genes that encode for proteins 
secreted by ESX-4 were cloned into two plasmids, pUAB300 and pUAB400. The plasmids 
each contain a fragment of mDHFR, which, when complete, confers resistance to the 
antibiotic trimethoprim. If the proteins of interest interact, the two fragments of mDHFR will 
be brought together and allow M. smegmatis to grow on plates containing trimethoprim. 
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Various combinations of proteins were electroporated into M. smegmatis cells, which were 
then plated out onto trimethoprim plates and allowed to grow. Growth indicates that the 
proteins do interact. Absence of growth indicates that the proteins do not interact. Knowing 
the way in which proteins interact and are secreted via the ESX-4 system is especially 
important to further understanding the mechanism by which DCT occurs. As it has been 
speculated that DCT and conjugation could be responsible for the genomic mosaicism seen 
in pathogenic mycobacteria, knowledge regarding the mechanism of the ESX-4, the most 
ancestral ESX system, could provide valuable insight (Gray et al., 2013). Identifying the 
interacting proteins will allow us to better understand the ESX-4 secretion system and T7SS 
within M. smegmatis.  
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Materials and Methods 
 
I. Q5 PCR of genes of interest 
 
 A total of seven proteins were identified as possible secreted partners from the ESX-4 
system due to the presence of WXG motifs within their structure and their chromosomal 
locations near or next to one another in the esx-4 gene locus. These proteins were confirmed 
to be present in M. smegmatis through a secretome analysis conducted previously. Two of 
these proteins, EsxU (MSMEG_1538) and EsxT (MSMEG_1539), are the primary WXG 
secretion substrates of ESX-4. They are similar to EsxA and EsxB from the ESX-1 system in 
M. tuberculosis which have been identified as important virulence factors (Figures 9 and 11). 
The second protein pair predicted to interact is encoded by the genes MSMEG_1560 and 
MSMEG_15750 because both contain WXG motifs and are also localized near each other 
(Figures 8 and 11). The last possibly interacting genes are a trio of proteins (MSMEG_1687, 
MSMEG_1686, and MSMEG_1685) that are all encoded one right after another within an 
operon (Figures 10 and 11). Of the three, 1686 is the largest with an ORF size of 
approximately 1 kb while 1685 and 1687 are about a third of that size. It is predicted that a 
combination of two or all three proteins will interact. 
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Figure 8. Modeled structures of proteins 
1560 and 15750. Created using Phyre2 
and colored by rainbow from the N to C 
terminus. 
 
Figure 9. Modeled structures of 
proteins EsxU and EsxT. Created 
using Phyre2 and colored by 
rainbow from the N to C terminus. 
 
Figure 10. Modeled structures of proteins 1685, 1686, and 1687. Created using Phyre2 and 
colored by rainbow from the N to C terminus. 
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In order to amplify the genes encoding the proteins of interest, Q5 PCR was 
performed. The PCR was performed utilizing gDNA from a specific recipient strain of M. 
smegmatis known as MKD8. The New England Biolab protocol was followed for a 50 μL 
reaction utilizing 5X Q5 Reaction Buffer, 10 mM dNTP’s, 10 μM forward primer, 10 μM 
reverse primer, Q5 High-Fidelity DNA polymerase, 5X Q5 High GC Enhancer, and nuclease 
free water was used to fill the reaction up to 50 10 μL. Dimethyl sulfoxide, DMSO, was also 
added in order to improve yield and specificity. The standard PCR procedure was followed 
utilizing an annealing temperature of 65°C. The PCR products were then visualized and 
confirmed using gel electrophoresis. After some preliminary interaction results were reported 
between MSMEG_1685 and MSMEG_1686, a new gene fragment was amplified that 
contained both genes in order to combine the dual fragment with MSMEG_1687 to see if the 
interaction was strengthened with the inclusion of all three proteins. Products were then 
purified utilizing the Qiagen PCR purification kit. 
Figure 11. Visual representation of the location of our seven proteins of interest within the 
MKD8 genome. 
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II. Vector construction and cloning 
 After purification, each gene fragment and the pUAB 300 and pUAB 400 plasmid 
backbones were digested with two enzymes. The fragments that were being cloned into 
pUAB 300 were digested with HindIII-HF and BamHI-HF. The fragments that were being 
cloned into pUAB 400 were digested with HindIII-HF and MfeI-HF (Figure 12). Digests 
were allowed to run for at least two hours or overnight. A small sample of each digest was 
then verified utilizing gel electrophoresis and after being confirmed, the digests were 
purified.  
 Each gene fragment was then combined with its corresponding vector and ligated 
together following the general ligation protocol for a 15 μL ligation. The ligated plasmid was 
then transformed into E. coli stellar cells via heat shock. The plasmid was combined with the 
stellar cells and then heat shocked at 42°C in the PCR machine or a water bath for one 
minute. Cells recovered on ice and then in 1 mL of SOC broth for an hour. Tubes were then 
spun down and then 100 μL of resuspended culture was plated on single antibiotic LB plates 
using a glass spreader and allowed to grow overnight. The plasmid pUAB 300 contains a 
marker for Hygromycin (Hyg) resistance so the bacteria containing pUAB 300 were grown 
on Hyg plates and the plasmid pUAB 400 contains a marker for Kanamycin (Kan) resistance 
so the bacteria containing pUAB 400 were grown on Kan plates. 
 4 mL cultures of terrific broth with added Kan or Hyg antibiotic were then made 
using two single colonies from the single antibiotic ligation plates and allowed to grow in a 
rotating wheel shaker overnight. Cultures were then miniprepped utilizing the Qiagen 
miniprep kit in order to isolate the plasmid. A diagnostic digest was then done with HindIII-
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HF and either BamHI-HF for pUAB 300 or MfeI-HF for pUAB 400 to ensure that the correct 
fragment had been inserted into the plasmid.  
 
Figure 12. Maps of plasmids pUAB 300 and pUAB 400 that were utilized in this assay. 
pUAB 300 contains a marker for Hyg resistance and recognition sites for the enzymes 
HindIII and BamHI. pUAB 400 contains a marker for Kan resistance and recognition sites 
for the enzymes HindIII and MfeI. Protein fragments were cloned into the plasmids between 
the enzyme digest sites.  
 
III. Electroporation into m𝒄𝟐155 M. smegmatis cells 
 
 After the plasmids had been digested and confirmed to have taken up the correct gene 
fragment, 500 ng of plasmid was electroporated into m𝑐$155 which is the standard lab strain 
of M. smegmatis. All time constants were around 19-22 milli-seconds which is the ideal for 
electroporation into M. smegmatis. The cells were then recovered in TSBtween broth for a 
minimum of 3 hours or overnight and then plated on TSA plates containing double antibiotic 
selection of Hyg and Kan. The cells were plated using a variety of methods including taking 
a loopful of the liquid culture, using a glass spreader with 100 μL of culture, or using a glass 
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spreader with 100 μL of spun down and resuspended bacterial culture. The plates were then 
allowed to grow in the 37 °C incubator for 3-4 days.  
 
IV. Assay Plating 
 
 Plates were poured utilizing 7H10 agar, 10x ADS, and a final concentration of 25 
μg/mL trimethoprim. In order to conduct the assay, cultures were made with 4 mL of 
TSBtween and 1 μL of Hyg and 1 μL of Kan along with a colony picked from the 
electroporation plates. The cultures were allowed to grow overnight or for however long it 
took to reach an optical density (O.D.) of around 1 at 6000 nm visible light wavelength. O.D. 
was measured using 500 μL of culture in a spectrophotometer.  If the cultures were above an 
O.D. of 1, the cultures were diluted back with TSBtween until they were an O.D. of 0.7 and 
then allowed to grow back to 1. This process was slightly subjective and we moved forward 
with plating as long as all the cultures were approximately the same O.D. 1 mL of neat, 
undiluted culture was measured out and a dilution series was done by transferring 100 μL of 
undiluted culture to 900 μL of TSBtween and then repeating that process down the line until 
four dilutions of the original undiluted culture were created. Then, 5 μL of each dilution was 
spotted on a TSA plate as the control and a 25 μg/mL Trimethoprim plate. The plates were 
then allowed to grow in the 37 °C incubator for 3-5 days and any growth was observed. 
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Results 
 
The first assay done was conducted utilizing EsxU in pUAB 300 and EsxT in pUAB 
400. M. smegmatis grew well on the TSA control plate on the left, indicating that the bacteria 
used for this assay were viable (Figure 13). The interaction on the top was the combination of 
proteins EsxU in pUAB 300 and EsxT in pUAB 400. Our data show there was growth on the 
25 μ g/mL trimethoprim plate indicating that the two proteins do interact (Figure 13). The 
interaction is strong, with the spotted colonies plated from the higher concentrations of 
culture resulting in large, defined colonies. The colonies on the assay plate are larger and 
more robust than the colonies on the control plate, indicating that M. smegmatis containing 
EsxU in pUAB 300 and EsxT in pUAB 400 were able to grow successfully, even in the 
presence of trimethoprim. On the bottom half of the plate, the combination of EsxU in pUAB  
300 and EsxU in pUAB 400 was included. It is possible that Esx proteins could self-
heterodimerize and be secreted together so same-protein combinations were included in our 
assays. Our data demonstrated that this was not the case for EsxU as no colony growth was 
observed on the trimethoprim assay plate (Figure 13). 
 
Figure 13. Assay with the trimethoprim (right) and the control TSA (left) plates containing 
the combination of EsxU in pUAB 300 and EsxT in pUAB 400 on the top half and the 
combination of EsxU in pUAB 300 and EsxU in pUAB 400 on the bottom half. 
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A second assay was conducted in order to confirm the EsxU in pUAB 300 and EsxT 
in pUAB 400 interaction, along with other protein combinations not yet tested. The first row 
consists of our positive control which was plasmids pUAB 100 and pUAB 200. Neither of 
these plasmids had any inserted gene fragments but both contained fragments of mDHFR 
which is brought together when combined. This positive control grew well on both the 
control TSA plate and the trimethoprim assay plate (Figure 14). The second row contains the 
combination of the protein pair 1560 in pUAB300 and 15750 in plasmid pUAB400. 
Although the colonies grew well on the control plate, no colony growth was observed on the 
trimethoprim, indicating that these proteins do not interact. Below that, we have the protein 
pair EsxT in pUAB 300 and EsxT in pUAB400. Again, there is a possibility that these 
proteins are able to self-heterodimerize and be secreted together so EsxT was included in a 
same-protein combination but no colony growth was observed on the trimethoprim plate, 
indicating that it does not self-interact. The next row has the EsxU in pUAB 300 and EsxT in 
pUAB400. This interaction again had clear, strong colony growth which in this assay, looks 
similar to the positive control (Figure 14). According to our data, we can conclude that EsxU 
in pUAB 300 and EsxT in pUAB 400 do interact as indicated by strong colony growth on the 
trimethoprim plates. And in the last row, we have the combination of 1686 in pUAB 300 and 
1685 in pUAB 400. This interaction was weaker than the EsxU and EsxT interaction and the 
colonies that grew on the control plate, but 1686/1685 still clearly demonstrated colony 
growth (Figure 14).  
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The third assay conducted was done in order to fully confirm the interaction between 
EsxU and EsxT. The top row of the plates contained the positive control of pUAB 100 and 
pUAB 200. Colonies grew well on both the control TSA plate on the left and the 
trimethoprim assay plate on the right (Figure 15). The next row down contained the 
combination of EsxU in pUAB 300 and EsxT in pUAB 400 that had previously been 
confirmed. But in this assay plating the interaction was not displayed and no colony growth 
was observed. The next row down contained pUAB 300 and pUAB 400 without any gene 
fragments as a negative control and no growth was observed on the trimethoprim assay plate 
but strong growth was observed on the control TSA plate. The second to last row contained 
the combination of EsxT in pUAB 300 and EsxU in pUAB 400. This combination was done 
to make sure that the previously observed interaction would still be present regardless of 
which plasmids the gene fragments were cloned into. Strong growth was observed, and the 
colonies looked similar to the interaction between EsxU in pUAB 300 and EsxT in pUAB 
Figure 14. Assay with trimethoprim (left) and TSA (right) plates with, going top to bottom, 
the positive control, 1560 (300) with 15750 (400), EsxT (300) with EsxT (400), EsxU (300) 
with EsxT (400), 1686 (300) with 1685 (400) on the bottom. 
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400 seen in previous assays (Figures 13, 14, and 15). The last row contained MKD10 cells 
without any plasmids electroporated into the bacteria as a last negative control. Growth was 
observed on the control TSA plate but not on the trimethoprim assay plate. 
 
 
 
 
 
 
 
 
 
 
Figure 15. Assay with the trimethoprim (right) and TSA (left) plates. Top row contains the 
positive control of pUAB 100 and pUAB 200. Next row down contains EsxU (300) and EsxT 
(400). Next down contains a negative control with empty pUAB 300 and pUAB 400. Below 
is EsxT (300) and EsxU (400). And the last row contains just MKD10 cells which act as 
another negative control.  
 
   
 
   
 
Boerboom 36 
Discussion 
 
 
 Our two-hybrid approach has preliminarily shown protein-protein interaction between 
EsxU and EsxT (Table 1). It demonstrated growth over multiple assay platings and it 
consistently grew on selective plates as well as the positive control. There was also 
interaction between EsxU and EsxT when the proteins were cloned into each plasmid 
indicating that the interaction occurs independent of what plasmid the protein has been 
cloned into (Figures 13, 14, 15). The only result that was slightly puzzling is that the 
combination of EsxU (300) and EsxT (400) did not grow on the third assay plating (Figure 
15). This combination had been demonstrated to grow various times before so it is likely that 
there was something wrong with the specific culture that was utilized in this assay plating. 
Bacterial strains are sometimes unstable and have to be re-derived or sequence verified. DNA 
sequencing had previously been done to confirm that the appropriate gene sequences had 
been properly inserted into the plasmids so it is unclear why the final assay did not 
demonstrate any interaction. In order to confirm our preliminary results, additional 
repetitions done with newly derived bacterial strains and plasmids are necessary. Lastly, 
neither combination of EsxU with EsxU and EsxT with EsxT demonstrated any interaction 
effect (Figures 13 and 14) so we have preliminary evidence to demonstrate that EsxU and 
EsxT do not heterodimerize and that the pair of both proteins are necessary for secretion. 
There was a demonstrated interaction between 1686 in pUAB 300 and 1685 in pUAB 
400 on the second assay plate which is interesting for a number of reasons (Figure 14). First, 
the interaction does not seem to be as strong as the one between the one between Esx U and 
Esx T. Although the colonies are smaller, and the colonies spotted from the more diluted 
cultures were very small or did not appear, the colonies that did grow were well formed and 
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clearly present. Second, it is interesting because proteins 1686 and 1685 are encoded in an 
operon of three genes consisting of 1687, 1686, and 1685 in that order (Figure 11). Neither 
1686 nor 1685 have the typical double helix structure of an ESX secreted substrate (Figure 
10). Out of that operon, 1687 is the only protein that has the clear helix-WXG-helix structure 
along with a secretion signal sequence. Our assay indicates that 1686 and 1685 interact and 
are able to be secreted as a pair even though they do not contain the typical characteristics of 
an ESX substrate. In order to determine if all three proteins interact, a gene fragment was 
generated that contains both 1686 and 1685. This gene fragment will be inserted into one of 
our plasmids in order to be electroporated with 1687. We predict that the interaction strength 
would possibly be increased with the inclusion of 1687 since it is the protein that contains the 
secretion signal sequence and it could possibly be necessary for efficient secretion.  
Lastly, we have consistent evidence that proteins 1560 and 15750 do not interact. 
During the initial trials of the assay, 1560 (300) and 15750 (400) were plated various times as 
they were two of the first gene fragments that were successfully cloned and electroporated 
into M. smegmatis. These initial trials were done to streamline the assay plating process and 
were done on 25 μg/mL trimethoprim plates along with a TSA control plate. This 
combination of proteins consistently did not demonstrate any interaction and during the 
formal assay plating, they did not interact. 1560 has the typical structure of an ESX secreted 
substrate but it does not seem to interact with 15750, which does not have the typical ESX 
substrate structure (Figure 8). It is possible that this pair of proteins requires additional 
conditions or proteins in order to interact but at this point it does not appear that they interact. 
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Table 1. Overview of our preliminary assay results. Protein pairs marked in green have been 
demonstrated to interact and protein pairs marked in red have been demonstrated to not 
interact. 
pUAB300 pUAB400 
Esx U Esx T 
Esx T Esx U 
Esx T Esx T 
Esx U Esx U 
1560 15750 
1686 1685 
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Conclusion 
 
 
 
 
 From the assays that we were able to conduct, we have received evidence to suggest 
that the protein pairs of EsxU/EsxT and 1686/1685 do interact. Along with those positive 
interactions, we were able to determine that 1560 and 15750 do not interact and that EsxU 
and EsxT do not self-interact (Figure 16). Moving forward, additional repetitions are 
necessary to confirm these findings. Additionally, each plasmid containing a gene fragment 
will be electroporated in combination with an empty plasmid that does not contain a fragment 
to ensure that any growth that is detected is due to the proteins themselves interacting and not 
the plasmids. Due to difficulties obtaining the correct gene fragments, not all interactions 
were tested so the next steps would be to complete the network of interactions to observe any 
other possible interactions. And in the future, we would want to also include interactions with 
Figure 16. Network of protein interactions that have been tested or that will be tested. The 
orange plasmids correspond to pUAB300 and the green plasmids correspond to pUAB400. Red 
arrows correspond to proteins that do not interact, green arrows correspond to proteins that do 
interact, and yellow arrows are proteins that have been demonstrated to interact. Thickness of 
arrows does not correspond to strength of interaction. 
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the various Ecc proteins encoded within the ESX-4 secretion mechanism since our current 
group of proteins could possibly be required for system stability and would interact with the 
actual transmembrane proteins themselves. 
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